

Medical Preferred Drug List (Marketplace) – July 2026

Prepared for Marketplace

Drug Class	Non-Preferred Product(s)	Preferred Product(s)
Acromegaly	Sandostatin® LAR Depot (octreotide) Signifor® LAR (pasireotide) Somavert® (pegvisomant) Somatuline Depot® (Lanreotide)	Ianreotide acetate (CIPLA)
Alpha-1 Antitrypsin Deficiency	Aralast® (Alpha-1-Proteinase Inhibitor) Glassia® (Alpha-1-Proteinase Inhibitor)	Prolastin C® (Alpha-1-Proteinase Inhibitor) Zemaira® (Alpha-1-Proteinase Inhibitor)
Antiviral-MAB-RSV		Beyfortus® (nirsevimab-alip) Enflonsia™ (clesrovimab-cfor)
Autoimmune	Actemra® (tocilizumab) IV Avtozma® (tocilizumab-anoh) Cimzia® (certolizumab pegol) Orencia® (abatacept) Cosentyx® (secukinumab) IV Omvoh® (mirikizumab-mrkz) Stelara® (ustekinumab) Imuldosa® (ustekinumab-srlf) Otulfi® (ustekinumab-aauz) Pyzchiva® (ustekinumab-ttwe) Steqeyma® (ustekinumab) Wezlana® (ustekinumab)	Entyvio® (vedolizumab) Ilumya™ (tilgrakizumab-asmn) Simponi Aria® (golimumab) Skyrizi® (risankizumab-rzaa) Tremfya® (guselkumab) Tofidence® (tocilizumab-bavi) Tyenne® (tocilizumab-aazg) Yesintek® (ustekinumab-kfce)
Autoimmune – Infliximab/Remicade	Remicade® (infliximab) Infliximab (unbranded) Zymfentra® (infliximab-dyyb)	Avsola® (infliximab-axxq) Inflectra® (infliximab-dyyb) Renflexis® (infliximab-abda)
Botulinum Toxins	Myobloc® (rimabotulinumtoxin B)	Botox® (onabotulinumtoxin A) Xeomin® (incobotulinumtoxin A) Daxxify® (daxibotulinumtoxin A-lanm) Dysport® (abobotulinumtoxin A)
Denosumab/Prolia/Xgeva Biosimilars	Prolia/Xgeva® (denosumab) Aukelso/Bosaya® (denosumab-kyqq) Bomynta/Conexence® (denosumab-bnht) Jubbonti/Wyost® (denosumab-bbdz)	Bildyos/Bilprevda® (denosumab-nxxp) Ospomyv/Xbryk® (denosumab-dssb) Stoboclo/Osenvelt® (denosumab-bmwo)
*Hematologic, Colony Stimulating Factors – Short Acting	Granix® (tbo-filgrastim) Leukine® (sargramostim) Neupogen® (filgrastim) Nypozi® (filgrastim-txid)	Zarxio® (filgrastim-sndz) Nivestym® (filgrastim-aafi) Releuko® (filgrastim-ayow)

*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. **Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Drug Class	Non-Preferred Product(s)	Preferred Product(s)
*Hematologic, Colony Stimulating Factors – Long Acting	Fylnetra® (pegfilgrastim-pbbk) Nyvepria™ (pegfilgrastim-apgf) Rolvedon® (eflapeggrastim-xnst) Stimufend® (pegfilgrastim-fpgk) Udenyca® (pegfilgrastim-cbqv) Ziextenzo® (pegfilgrastim-bmez) Ryzneuta® (efbemalenograstim-alfa)	Fulphila™ (pegfilgrastim-jmdb) Neulasta® (pegfilgrastim)
Hematologic, Erythropoiesis-Stimulating Agents	Epogen® (epoetin alfa) Procrit® (epoetin alfa) Retacrit® (epoetin alfa-epbx)	Aranesp® (darbepoetin) Mircera® (methoxy polyethylene glycol-epoetin beta)
Heme, IV Iron	Injectafer® (ferric carboxymaltose) Monoferric® (ferric derisomaltose)	Ferrlecit® (sodium ferric gluconate) Feraheme® (ferumoxytol) Infed® (Iron dextran) Venofer® (iron sucrose)
Hemophilia, Factor VIII	Helixate® [Antihemophilic Factor (recombinant), Formulated with Sucrose] Recombinate® [Antihemophilic Factor (recombinant)]	Advate® [antihemophilic factor (recombinant)] Afstyla® [antihemophilic factor (recombinant)] Adynovate® [antihemophilic factor (recombinant), PEGylated] Eloctate® (antihemophilic factor recombinant Fc fusion protein) Jivi® [antihemophilic factor (recombinant), PEGylated] Kogenate® [antihemophilic factor (recombinant)] Kovaltry® [antihemophilic factor (recombinant)] Novoeight® [antihemophilic factor (recombinant)] Nuwiq® [antihemophilic Factor (recombinant)] Xyntha® [antihemophilic Factor (recombinant)]
Immune Globulin – IV	Asceniv® (immune globulin) Carimune® (immune globulin) Gammaplex® (immune globulin) Panzyga® (immune globulin) Vivaglobin® (immune globulin)	Bivigam® (immune globulin) Flebogamma® (immune globulin) Gammagard® (immune globulin) Gammagard S/D® (immune globulin) Gamunex-C® (immune globulin) Gammaked® (immune globulin) Octagam® (immune globulin) Privigen® (immune globulin)
Long-Acting Reversible Contraceptives		Kyleena® (levonorgestrel-releasing intrauterine system) Mirena® (levonorgestrel-releasing intrauterine system) Skyla® (levonorgestrel-releasing

*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. **Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. ***See Rituximab & Trastuzumab sections.



Drug Class	Non-Preferred Product(s)	Preferred Product(s)
		intrauterine system) Liletta® (levonorgestrel-releasing intrauterine system) Nexplanon® (etonogestrel implant) Paragard® (intrauterine copper)
Lysosomal Storage Disorders – Gaucher Disease	VPRIV® (velaglucerase alfa)	Cerezyme®(imiglucerase) Elelyso® (taliglucerase alfa)
Multiple Sclerosis (Infused)	Lemtrada® (alemtuzumab) Ocrevus Zunovo® (ocrelizumab-hyaluronidase) Tyruko® (natalizumab)	Tysabri® (natalizumab) Ocrevus® (ocrelizumab) Briumvi® (ublituximab-xiiy)
Myasthenia Gravis/Paroxysmal Nocturnal Hemoglobinuria (PNH)	Empaveli® (pegcetaclopan) Soliris® (eculizumab) Ultomiris® (Ravulizumab-cwrz)	Bkemv® (eculizumab) Epysqli® (eculizumab)
Osteoarthritis, Viscosupplements, Single Injection	Durolane® (hyaluronic acid) Gel-One® (sodium hyaluronate)	Monovisc® (sodium hyaluronate) Synvisc ONE® (hylan (Avian) 8 mg/mL)
Osteoarthritis, Viscosupplements, Multi Injection	Gelsyn-3® (sodium hyaluronate) GenVisc® 850 (sodium hyaluronate) Hyalgan® (1% sodium hyaluronate) Hymovis (sodium hyaluronate) Supartz® FX (1% sodium hyaluronate) SynoJoynt® (1% sodium hyaluronate) Synvisc (hylan (Avian) 8 mg/mL) Triluron® (sodium hyaluronate) TriVisc®(sodium hyaluronate) Visco-3® (1% sodium hyaluronate)	Euflexxa® (1% sodium hyaluronate) Orthovisc® (1% sodium hyaluronate)
Oncology – IV with SC Formulations	Darzalex Faspro® (daratumumab-hyaluronidase-fihj) Keytruda Qlex™ (pembrolizumab-berahyaluronidase alfa-pmph) Opdivo Qvantig™ (nivolumab-hyaluronidase-nvyh) Tecentriq Hybreza™ (atezolizumab-hyaluronidase-tqrs) ***Herceptin Hylecta™ & Rituxan Hycela® (refer to their sections for preferred products)	Darzalex® (daratumumab) Keytruda® (pembrolizumab) Opdivo® (nivolumab) Tecentriq® (atezolizumab)
*Oncology	**Avastin® (bevacizumab) Vegzelma® (bevacizumab-adcd) Zirabev® (bevacizumab-bvzr) Herceptin® (trastuzumab) Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) Hercessi® (trastuzumab-strf) Herzuma® (trastuzumab-pkrb) Ogivri™ (trastuzumab-dkst) Ontruzant® (trastuzumab-dttb)	Mvasi™ (bevacizumab-awwb) AlymSYS® (bevacizumab-maly) ***Kanjinti™ (trastuzumab-anns) ***Trazimera™ (trastuzumab-qyyp)

*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. **Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. ***See Rituximab & Trastuzumab sections.



Drug Class	Non-Preferred Product(s)	Preferred Product(s)
*Rituximab	Rituxan® (rituximab) Rituxan Hycela®(rituximab-hyaluronidase) Riabni™ (rituximab-arrx)	***Ruxience®(rituximab-pvvr) ***Truxima®(rituximab-abbs)
Retinal Disorders (Eye)	Ahzantive® (aflibercept) Beovu® (brolucizumab-dbll) Byooviz®(ranibizumab) Cimerli® (ranibizumab-eqrn) Enzeevu® (aflibercept) Macugen® (pegaptanib) Opuviz® (aflibercept) Pavblu® (aflibercept) Susvimo™ (ranibizumab) Vabysmo™ (faricimab-svoa) Visudyne® (verteporfin)	1a – Preferred overall: • **Avastin® (bevacizumab) 1b - Preferred over ranibizumab biosimilars & Eylea®: • Lucentis® (ranibizumab)
		2 - Preferred over aflibercept biosimilars: • Eylea® (aflibercept)

*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. **Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. ***See Rituximab & Trastuzumab sections.

